Evoke Pharma, Inc.
EVOK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 14.2% | 21.8% | -6.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 97.6% | 95.5% | 98.6% | 96.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -24% | -38.5% | -38.4% | -32.2% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -27% | -41.9% | -42.4% | -36.1% |
| EPS Diluted | -0.45 | -0.62 | -0.51 | -0.8 |
| % Growth | 27.4% | -21.6% | 36.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |